First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC

In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).

Related Keywords

Byoung Chul Cho , Yonsei University College Of Medicine , International Association , Lung Cancer , Chul Cho , Medical Oncology , Yonsei Cancer Center , Yonsei University College , Bill Grossman , Evoke 02 , Nsclc , Sacituzumab Govitecan , Pembrolizumab ,